Program
sonesitatug vedotin
Also written as “AZD0901”, “Sonesitatug Vedotin” and “Sonesitatug vedotin”.
Its studies are mostly in Stomach Neoplasms · Pancreatic Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 66 open or running | phase 3since Feb 28, 2024 | Dec 7, 2022 | Nov 17, 2026phase 2 · NCT06219941 |
| Keymed Biosciences | 10 open or running | phase 1since Mar 16, 2021 | Mar 16, 2021 | none ahead |
- Named in AstraZeneca’s own pipeline as
sonesitatug vedotin
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 16, 2021First study: phase 1 study in Pancreatic NeoplasmsNew to Keymed BiosciencesKeymed Biosciences · NCT04805307 · 176 enrolled · China
- Dec 7, 2022AstraZeneca's first study: phase 2 study in Stomach NeoplasmsNew to AstraZenecaAstraZeneca · NCT05702229 · 163 planned · United States, China, Japan and more
- Nov 21, 2023Phase 2 study in Stomach NeoplasmsAstraZeneca · NCT06219941 · 226 planned · United States, Australia, Canada and more
- Feb 28, 2024Phase 3 study in Stomach NeoplasmsAstraZeneca · NCT06346392 · 594 enrolled · United States, Brazil, Canada and more
- Jun 24, 2025Phase 2 study in Stomach NeoplasmsAstraZeneca · NCT07069712 · 100 planned · United States, Canada, China and more
- Aug 20, 2025Phase 2 study in Stomach NeoplasmsAstraZeneca · NCT07143604 · 33 enrolled · Russia
- Jan 16, 2026Phase 3 study in Stomach NeoplasmsAstraZeneca · NCT07431281 · 2,130 planned · United States, Australia, Austria and more
Ahead
- Nov 17, 2026Primary completion: phase 2 study in Stomach NeoplasmsAstraZeneca · NCT06219941
- Nov 9, 2027Primary completion: phase 2 study in Stomach NeoplasmsAstraZeneca · NCT07069712
- Nov 30, 2027Primary completion: phase 2 study in Stomach NeoplasmsAstraZeneca · NCT05702229
- Aug 16, 2029Primary completion: phase 3 study in Stomach NeoplasmsAstraZeneca · NCT07431281
TargetBeta
“An antibody-drug conjugate (ADC) composed of sonesitatug, a monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), conjugated, via a cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), w…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of sonesitatug, a monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), ”NCIt, by rule
Other programs on CLDN18
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zolbetuximabrule | Astellas Pharma | phase 4 | 12 |
| garetatug rezetecan | Jiangsu HengRui Medicine | phase 3 | 7 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905rule | Qilu Pharmaceutical | phase 3 | 6 |
| tecotabart vedotin | Sino Biopharmaceutical | phase 3 | 6 |
| arcotatug tavatecanrule | Innovent Biologics | phase 3 | 5 |
| terallethrinrule | FutureGen Biopharmaceutical (Beijing) | phase 3 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1 | biokin-shanghai-biopharmaceutical-co-ltd | phase 3 | 3 |
| emaretamigrule | Astellas Pharma | phase 3 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200rule | Sichuan Kelun Pharmaceutical | phase 2 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate ASP546Crule | Astellas Pharma | phase 2 | 2 |
| givastomigrule | i-mab-biopharma-us-limited | phase 2 | 2 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863 | AstraZeneca | phase 2 | 1 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07431281Stomach Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | AstraZeneca | Aug 16, 2029 | 2,130 |
| NCT07143604Stomach Neoplasms · Russia | 2 | Active, not recruiting | AstraZeneca | Aug 14, 2026 | 33 |
| NCT07069712Stomach Neoplasms · United States, Canada, China and more | 2 | Recruiting | AstraZeneca | Nov 9, 2027 | 100 |
| NCT06346392Stomach Neoplasms · United States, Brazil, Canada and more | 3 | Active, not recruiting | AstraZeneca | May 31, 2026 | 594 |
| NCT06219941Stomach Neoplasms · United States, Australia, Canada and more | 2 | Recruiting | AstraZeneca | Nov 17, 2026 | 226 |
| NCT05702229Stomach Neoplasms · United States, China, Japan and more | 2 | Recruiting | AstraZeneca | Nov 30, 2027 | 163 |
| NCT04805307Pancreatic Neoplasms · China | 1 | Completed | Keymed Biosciences | Apr 5, 2024 | 176 |
How it is read
Names in the registry
- “AZD0901”, 5 entries
- “Sonesitatug Vedotin”, 1 entry
- “Sonesitatug vedotin”, 1 entry
- “CMG901”, 1 entry
Conditions, from the studies’ own filings
- Stomach Neoplasms, 6 studies
- Pancreatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.